Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has issued an update.
Zydus Lifesciences Limited reported a strong operational performance for the third quarter of FY26, with revenue from operations rising 30% year-on-year to Rs. 68,645 million and EBITDA up 31%, delivering a margin of 26.5%. The company invested Rs. 6,074 million in R&D during the quarter, maintained robust profitability with adjusted net profit of Rs. 11,109 million, and continued organic capex of Rs. 4,637 million.
For the nine months ended December 31, 2025, revenue grew 17% to Rs. 195,614 million, while EBITDA increased 20% with an improved margin of 30.3%. Adjusted net profit rose 15% to Rs. 38,640 million, and the balance sheet remained conservative with a net debt-to-equity ratio of 0.11x and net debt-to-EBITDA of 0.36x, underscoring financial strength to support ongoing R&D and capacity expansion.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited is an India-based pharmaceutical company engaged in developing, manufacturing and marketing generic and specialty medicines. The company focuses on research-driven growth, with a significant share of revenue reinvested into R&D to strengthen its pipeline and competitiveness across domestic and international markets.
Average Trading Volume: 20,583
Technical Sentiment Signal: Hold
Current Market Cap: 893.4B INR
Learn more about ZYDUSLIFE stock on TipRanks’ Stock Analysis page.